Enzyme

<h3 id="key-highlights">Key Highlights</h3>
<ul>
 <li>Anthropic launched a biology wet lab staffed with human researchers in the Bay Area, operating discreetly since spring 2026.</li>
 <li>The facility combined Claude AI agents with human biologists to analyze DNA sequences for undiscovered enzyme capabilities.</li>
 <li>Scientists identified a novel enzyme system dubbed array-associated reverse transcriptases (ART), exhibiting CRISPR-like properties.</li>
 <li>The breakthrough resulted from 950 Claude agents analyzing more than 200,000 potential enzymes within 24 hours.</li>
 <li>The company has clarified it won’t conduct clinical trials and isn’t positioning itself as a pharmaceutical competitor.</li>
</ul>
Anthropic has <a href="https://www.forbes.com/sites/renanaashkenazi/2026/09/25/why-wall-street-got-anthropics-big-dna-discovery-so-wrong/" rel="noopener noreferrer nofollow">verified</a> the establishment of a wet laboratory focused on biological research. This facility operates in the San Francisco Bay Area and has been functional since spring of this year.
<div class="embed-x">
 <blockquote class="twitter-tweet">
 Today we announced the Claude-led discovery of a molecular machine that we suspect could represent a new gene editing mechanism. Its precise function, biotechnological utility (if any), or level of significance is not yet clear, but at minimum it is work I would have been proud… <a href="https://t.co/hyzhzirNJe" rel="noopener noreferrer nofollow">https://t.co/hyzhzirNJe</a>
 — Dario Amodei (@DarioAmodei) <a href="https://x.com/DarioAmodei/status/2102831170299834652?ref_src=twsrc%5Etfw" rel="noopener noreferrer nofollow">September 23, 2026</a>
 </blockquote>
</div>
The organization maintained silence about this initiative until recent days. The announcement revealed the laboratory had successfully completed its inaugural scientific discovery.
Claude, Anthropic’s AI system, was deployed to examine extensive DNA sequence databases. The objective centered on identifying proteins and enzymes that remained understudied by the scientific community.
<h3 id="the-research-methodology">The Research Methodology</h3>
The investigation began with a straightforward query directing Claude to identify novel reverse transcriptase capabilities. These enzymes function by transcribing RNA into DNA sequences.
The company deployed 950 Claude AI agents to execute this analysis within a 24-hour period. Collectively, these agents compiled over 200,000 potential enzyme candidates.
Researchers subsequently filtered this extensive list down to 20 particularly promising options. Interestingly, one candidate had previous documentation, but the AI system identified previously unrecognized features.
This enzyme displayed a distinctive repeating DNA sequence pattern. Such patterns correlate with mechanisms used by CRISPR technology to modify genetic sequences.
The newly identified enzyme system received the designation array-associated reverse transcriptases, abbreviated as ART. Anthropic released a technical document detailing the discovery, though independent peer review remains pending.
In an interview with Reuters, Eric Kauderer-Abrams, who leads life sciences at Anthropic, discussed the facility. He noted the laboratory maintains the appearance and equipment of a standard molecular biology research center.
Kauderer-Abrams clarified that the primary distinction lies in the preliminary research phase. Claude handles the initial sequence scanning and candidate identification tasks.
Human researchers subsequently conduct experimental validation on the prioritized candidates. Kauderer-Abrams emphasized that conclusive verification must occur through physical laboratory experimentation rather than computational analysis alone.
<h3 id="future-implications-and-industry-response">Future Implications and Industry Response</h3>
Feng Zhang, a CRISPR technology pioneer affiliated with MIT and the Broad Institute, provided perspective on the finding. He characterized it as a demonstration of AI agents’ potential contributions to biological science.
Zhang noted the relationship between this enzyme and RNA repeat sequences merits additional investigation. Scientists have yet to fully determine ART’s complete biological function.
Anthropic emphasized its research initiative remains distinct from pharmaceutical development efforts. The organization confirmed it has no plans to conduct clinical trials connected to this research.
In his Reuters interview, Kauderer-Abrams clarified that Anthropic doesn’t view itself as a rival to pharmaceutical and biotechnology corporations. He explained these companies concentrate on commercializing therapeutic products, which falls outside Anthropic’s mission.
The company maintains partnerships with pharmaceutical firms such as Roche, Genentech, and Bristol Myers Squibb. While these organizations may utilize Anthropic’s AI technology, Anthropic’s proprietary laboratory possesses capabilities unavailable to external academic researchers.
Certain members of the research community have expressed financial apprehensions. The Scientist publication reported in July that academics face difficult decisions between allocating funds for AI processing tokens versus supporting graduate students and postdoctoral researchers.
The ART discovery credited six named human scientists collaborating with Claude. The research consumed 210 million tokens throughout the search and analytical phases.
Additional technology companies are pursuing AI-enhanced biological research. Both Alphabet’s Isomorphic Labs and OpenAI have released findings in this domain during recent months.
The post <a href="https://blockonomi.com/anthropics-claude-ai-discovers-novel-crispr-like-enzyme-system-in-groundbreaking-research/" rel="noopener noreferrer nofollow">Anthropic’s Claude AI Discovers Novel CRISPR-Like Enzyme System in Groundbreaking Research</a> appeared first on <a href="https://blockonomi.com" rel="noopener noreferrer nofollow">Blockonomi</a>.

Anthropic’s Claude AI Discovers Novel CRISPR-Like Enzyme System in Groundbreaking Research

Table of Contents

Blockonomi

Other articles published on Sep 25, 2026

Join our free newsletter for daily crypto updates!